Andere Kunden interessierten sich auch für
![Direct treatment cost under private health insurance in Delhi, India]( "Direct treatment cost under private health insurance in Delhi, India")
Direct treatment cost under private health insurance in Delhi, India36,99 €![Cost-Effectiveness Analysis of DAT and rK39]( "Cost-Effectiveness Analysis of DAT and rK39")
Cost-Effectiveness Analysis of DAT and rK3926,99 €![Analysis of the financial and social performance of mutual health insurance companies]( "Analysis of the financial and social performance of mutual health insurance companies")
Analysis of the financial and social performance of mutual health insurance companies26,99 €![Is patient education program for people with diabetes mellitus cost-effective?]( "Is patient education program for people with diabetes mellitus cost-effective?")
Is patient education program for people with diabetes mellitus cost-effective?57,99 €![Cost-Effectiveness of Introducing Pneumococcal Vaccination Programme]( "Cost-Effectiveness of Introducing Pneumococcal Vaccination Programme")
Cost-Effectiveness of Introducing Pneumococcal Vaccination Programme45,99 €![Telenephrology as a cost-benefit tool in public health]( "Telenephrology as a cost-benefit tool in public health")
Telenephrology as a cost-benefit tool in public health26,99 €![Evaluation of the cost of epilepsy care in sub-Saharan Africa]( "Evaluation of the cost of epilepsy care in sub-Saharan Africa")
Evaluation of the cost of epilepsy care in sub-Saharan Africa26,99 €
"Alpha-1 Antitrypsin Deficiency (AATD) Financial Cost" provides an in-depth analysis of the financial burdens associated with Alpha-1 Antitrypsin Deficiency (AATD), referencing 14 unique research studies. These studies cover various aspects of medical expenses, including augmentation therapy, hospitalization, emergency care, outpatient care, and the long-term financial impact on patients and families. The book offers valuable insights into the economic challenges faced by AATD patients and their families, helping them make informed decisions about treatment options, insurance coverage, and resource allocation.The book contributes to the development of healthcare strategies by highlighting the cost-effectiveness of various treatment options and identifying areas where financial support is needed. It brings innovative ideas and research by examining emerging treatments, such as gene therapy and small molecule therapies, and their economic impact. Additionally, the book offers strategies for reducing healthcare costs and improving the overall quality of life for AATD patients. This comprehensive approach makes it a valuable resource for anyone interested in the financial aspects of healthcare and the management of Alpha-1 Antitrypsin Deficiency.